Injectable cholesterol lowering medications
Pro Research Analysisby 
Searched over 200M research papers
Overview of Injectable Cholesterol Lowering Medications
Injectable cholesterol-lowering medications have become important options for patients who cannot reach their cholesterol goals with oral therapies like statins, or for those who are statin intolerant. These drugs are especially useful for people at high risk of cardiovascular disease or with inherited forms of high cholesterol 128.
Types of Injectable Cholesterol Lowering Drugs
PCSK9 Inhibitors: Evolocumab, Alirocumab, and Ongericimab
PCSK9 inhibitors, such as evolocumab and alirocumab, are monoclonal antibodies that block the PCSK9 protein, which leads to increased recycling of LDL receptors and greater removal of LDL cholesterol from the blood. These drugs are approved for patients with cardiovascular disease and familial hypercholesterolemia 128. Ongericimab, a newer anti-PCSK9 antibody, has also shown strong LDL cholesterol reduction in clinical trials, with a decrease of over 70% in LDL-C after 12 weeks, and was well tolerated with similar rates of side effects as placebo .
Small Interfering RNA (siRNA) Therapy: Inclisiran
Inclisiran is a first-in-class siRNA therapy that works by blocking the production of PCSK9 at the genetic level. It is injected twice a year and is approved for adults with atherosclerotic cardiovascular disease or familial hypercholesterolemia who need further LDL-C reduction despite maximally tolerated statin therapy. Clinical trials have shown that inclisiran can lower LDL-C by about 40–51%, with side effects similar to placebo except for mild injection site reactions 1569.
Antisense Oligonucleotides: Mipomersen and Others
Mipomersen is an antisense oligonucleotide that targets the mRNA for apolipoprotein B100, reducing LDL cholesterol. It is mainly associated with side effects like liver fat accumulation, increased liver enzymes, injection site reactions, and flu-like symptoms. Its long-term safety profile is still being studied 12.
Other Emerging Injectable Therapies
Other injectable drugs in development target proteins like angiopoietin-like protein 3 (e.g., evinacumab, IONIS-ANGPTL3Rx) and have shown promise, but their safety and effectiveness in broader patient populations are still under investigation .
Safety and Tolerability of Injectable Cholesterol Medications
PCSK9 inhibitors (evolocumab, alirocumab, ongericimab) and inclisiran have demonstrated good safety and tolerability in clinical trials, with most side effects being mild, such as injection site reactions, nasopharyngitis, joint pain, and back pain. Serious side effects are rare and occur at rates similar to placebo 1256+2 MORE. Mipomersen and similar drugs may have more significant side effects, particularly related to the liver, and require further long-term safety data 12.
Physician and Patient Preferences
Physicians, especially cardiologists, often prefer injectable therapies for patients who have trouble adhering to daily oral medications. Less frequent dosing, such as every six months with inclisiran, is seen as an advantage for improving adherence in real-world practice . Efficacy in lowering LDL-C is the most important factor for prescribers, followed by cost and convenience .
Conclusion
Injectable cholesterol-lowering medications, including PCSK9 inhibitors, siRNA therapies like inclisiran, and antisense oligonucleotides, offer effective and generally well-tolerated options for patients who need additional LDL-C reduction beyond what oral therapies can provide. These drugs are especially valuable for high-risk patients and those with adherence challenges. Ongoing research will further clarify their long-term safety and impact on cardiovascular outcomes 1256+4 MORE.
Sources and full results
Most relevant research papers on this topic